0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global BCMA-targeted CAR-T Cell Therapy Market Research Report 2026
Published Date: 2026-01-26
|
Report Code: QYRE-Auto-4R18741
Home | Market Reports | Health| Health Conditions| Cancer
Global BCMA targeted CAR T Cell Therapy Market Research Report 2024
BUY CHAPTERS

Global BCMA-targeted CAR-T Cell Therapy Market Research Report 2026

Code: QYRE-Auto-4R18741
Report
2026-01-26
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

BCMA-targeted CAR-T Cell Therapy Market Size

The global BCMA-targeted CAR-T Cell Therapy market was valued at US$ 1803 million in 2025 and is anticipated to reach US$ 8425 million by 2032, at a CAGR of 25.0% from 2026 to 2032.

BCMA-targeted CAR-T Cell Therapy Market

BCMA-targeted CAR-T Cell Therapy Market

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. Currently available CAR-T cell therapy products are divided into CD19 targets and BCMA targets. BCMA stands for B - cell maturation antigen. It is a protein that is found on the surface of plasma cells, which are abnormal cells that multiply uncontrollably in multiple myeloma, a type of blood cancer. By targeting BCMA, the CAR - T cell therapy aims to specifically attack the cancer - causing plasma cells.
Major players: The BCMA-targeted CAR-T cell therapy market presents a highly concentrated duopoly. In 2024, the global market CR2 index exceeded 98%. The main products are Carvykti (Cedacion) jointly developed by Legend Biotech and Johnson & Johnson and Abecma of Bristol-Myers Squibb. Among them, Carvykti continues to expand its market leadership with significant clinical advantages, and its global sales in 2024 increased by 93% year-on-year. In contrast, Abecma's sales in the current period decreased by about 14% year-on-year due to intensified market competition and product iteration pressure.
Market Trends: The BCMA CAR - T cell therapy market is in a phase of rapid growth. The reasons for this growth are two - fold. Firstly, there is a large population of patients with multiple myeloma, and there are many unmet medical needs. Secondly, this therapy has demonstrated good efficacy and has been recognized by the market. With the maturation of technology and market promotion, it is expected that the market will maintain a high growth rate in the coming years.
Expansion of Indications: Currently, BCMA CAR - T cell therapy is mainly used for the treatment of relapsed or refractory multiple myeloma. With the deepening of research, its indications are expected to be broadened. Pre - clinical and clinical trials are exploring its application in other hematological malignancies, such as certain types of leukemia and lymphoma. If successful, this will greatly expand the market size, bring hope to more patients, and inject new impetus into the growth of the therapy market.
Changing Competitive Landscape:The market competition is becoming increasingly fierce. In addition to the already - launched products such as Ciltacabtagene Autoleucel (Carvykti) and Idecabtagene Vicleucel (Abecma), many pharmaceutical companies are actively deploying and researching BCMA CAR - T products. New entrants may change the existing competitive landscape with innovative technologies or better cost control.
High - Cost Constraints: The research, development, and production processes of BCMA CAR - T cell therapy are complex, involving multiple high - cost links such as cell collection, gene editing, and cell culture, resulting in high product prices. This makes it difficult for many patients to afford, limiting the accessibility of the therapy and, to a certain extent, hindering the rapid expansion of the market. How to reduce costs so that more patients can benefit is an important challenge faced by the entire industry.
Safety Risks:Although this therapy has achieved remarkable results in clinical applications, there are still certain safety risks, such as cytokine release syndrome (CRS) and neurotoxicity. These adverse reactions may have a serious impact on the health of patients and even endanger their lives.
This report delivers a comprehensive overview of the global BCMA-targeted CAR-T Cell Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding BCMA-targeted CAR-T Cell Therapy. The BCMA-targeted CAR-T Cell Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global BCMA-targeted CAR-T Cell Therapy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist BCMA-targeted CAR-T Cell Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of BCMA-targeted CAR-T Cell Therapy Market Report

Report Metric Details
Report Name BCMA-targeted CAR-T Cell Therapy Market
Accounted market size in 2025 US$ 1803 million
Forecasted market size in 2032 US$ 8425 million
CAGR 25.0%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Abecma
  • Carvykti
  • Others
Segment by Application
  • Hospital
  • Oncology Clinic
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Nanjing Legend Biotechnology/J&J (Carvykti), Bristol-Myers Squibb (Abecma), CARsgen, Nanjing Iaso Biotherapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for BCMA-targeted CAR-T Cell Therapy companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is BCMA-targeted CAR-T Cell Therapy Market growing?

Ans: The BCMA-targeted CAR-T Cell Therapy Market witnessing a CAGR of 25.0% during the forecast period 2026-2032.

What is the BCMA-targeted CAR-T Cell Therapy Market size in 2032?

Ans: The BCMA-targeted CAR-T Cell Therapy Market size in 2032 will be US$ 8425 million.

What is the BCMA-targeted CAR-T Cell Therapy Market share by type?

Ans: Among them, Carvykti continues to expand its market leadership with significant clinical advantages, and its global sales in 2024 increased by 93% year-on-year. In contrast, Abecma's sales in the current period decreased by about 14% year-on-year due to intensified market competition and product iteration pressure.

Who are the main players in the BCMA-targeted CAR-T Cell Therapy Market report?

Ans: The main players in the BCMA-targeted CAR-T Cell Therapy Market are Nanjing Legend Biotechnology/J&J (Carvykti), Bristol-Myers Squibb (Abecma), CARsgen, Nanjing Iaso Biotherapeutics

What are the Application segmentation covered in the BCMA-targeted CAR-T Cell Therapy Market report?

Ans: The Applications covered in the BCMA-targeted CAR-T Cell Therapy Market report are Hospital, Oncology Clinic

What are the Type segmentation covered in the BCMA-targeted CAR-T Cell Therapy Market report?

Ans: The Types covered in the BCMA-targeted CAR-T Cell Therapy Market report are Abecma, Carvykti, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Abecma
1.2.3 Carvykti
1.2.4 Others
1.3 Market by Application
1.3.1 Global BCMA-targeted CAR-T Cell Therapy Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Oncology Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global BCMA-targeted CAR-T Cell Therapy Market Perspective (2021–2032)
2.2 Global BCMA-targeted CAR-T Cell Therapy Growth Trends by Region
2.2.1 Global BCMA-targeted CAR-T Cell Therapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 BCMA-targeted CAR-T Cell Therapy Historic Market Size by Region (2021–2026)
2.2.3 BCMA-targeted CAR-T Cell Therapy Forecasted Market Size by Region (2027–2032)
2.3 BCMA-targeted CAR-T Cell Therapy Market Dynamics
2.3.1 BCMA-targeted CAR-T Cell Therapy Industry Trends
2.3.2 BCMA-targeted CAR-T Cell Therapy Market Drivers
2.3.3 BCMA-targeted CAR-T Cell Therapy Market Challenges
2.3.4 BCMA-targeted CAR-T Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top BCMA-targeted CAR-T Cell Therapy Players by Revenue
3.1.1 Global Top BCMA-targeted CAR-T Cell Therapy Players by Revenue (2021–2026)
3.1.2 Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Players (2021–2026)
3.2 Global Top BCMA-targeted CAR-T Cell Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by BCMA-targeted CAR-T Cell Therapy Revenue
3.4 Global BCMA-targeted CAR-T Cell Therapy Market Concentration Ratio
3.4.1 Global BCMA-targeted CAR-T Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by BCMA-targeted CAR-T Cell Therapy Revenue in 2025
3.5 Global Key Players of BCMA-targeted CAR-T Cell Therapy Head Offices and Areas Served
3.6 Global Key Players of BCMA-targeted CAR-T Cell Therapy, Products and Applications
3.7 Global Key Players of BCMA-targeted CAR-T Cell Therapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 BCMA-targeted CAR-T Cell Therapy Breakdown Data by Type
4.1 Global BCMA-targeted CAR-T Cell Therapy Historic Market Size by Type (2021–2026)
4.2 Global BCMA-targeted CAR-T Cell Therapy Forecasted Market Size by Type (2027–2032)
5 BCMA-targeted CAR-T Cell Therapy Breakdown Data by Application
5.1 Global BCMA-targeted CAR-T Cell Therapy Historic Market Size by Application (2021–2026)
5.2 Global BCMA-targeted CAR-T Cell Therapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America BCMA-targeted CAR-T Cell Therapy Market Size (2021–2032)
6.2 North America BCMA-targeted CAR-T Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America BCMA-targeted CAR-T Cell Therapy Market Size by Country (2021–2026)
6.4 North America BCMA-targeted CAR-T Cell Therapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe BCMA-targeted CAR-T Cell Therapy Market Size (2021–2032)
7.2 Europe BCMA-targeted CAR-T Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe BCMA-targeted CAR-T Cell Therapy Market Size by Country (2021–2026)
7.4 Europe BCMA-targeted CAR-T Cell Therapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size (2021–2032)
8.2 Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size by Region (2021–2026)
8.4 Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America BCMA-targeted CAR-T Cell Therapy Market Size (2021–2032)
9.2 Latin America BCMA-targeted CAR-T Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America BCMA-targeted CAR-T Cell Therapy Market Size by Country (2021–2026)
9.4 Latin America BCMA-targeted CAR-T Cell Therapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Size (2021–2032)
10.2 Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Size by Country (2021–2026)
10.4 Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nanjing Legend Biotechnology/J&J (Carvykti)
11.1.1 Nanjing Legend Biotechnology/J&J (Carvykti) Company Details
11.1.2 Nanjing Legend Biotechnology/J&J (Carvykti) Business Overview
11.1.3 Nanjing Legend Biotechnology/J&J (Carvykti) BCMA-targeted CAR-T Cell Therapy Introduction
11.1.4 Nanjing Legend Biotechnology/J&J (Carvykti) Revenue in BCMA-targeted CAR-T Cell Therapy Business (2021–2026)
11.1.5 Nanjing Legend Biotechnology/J&J (Carvykti) Recent Development
11.2 Bristol-Myers Squibb (Abecma)
11.2.1 Bristol-Myers Squibb (Abecma) Company Details
11.2.2 Bristol-Myers Squibb (Abecma) Business Overview
11.2.3 Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Introduction
11.2.4 Bristol-Myers Squibb (Abecma) Revenue in BCMA-targeted CAR-T Cell Therapy Business (2021–2026)
11.2.5 Bristol-Myers Squibb (Abecma) Recent Development
11.3 CARsgen
11.3.1 CARsgen Company Details
11.3.2 CARsgen Business Overview
11.3.3 CARsgen BCMA-targeted CAR-T Cell Therapy Introduction
11.3.4 CARsgen Revenue in BCMA-targeted CAR-T Cell Therapy Business (2021–2026)
11.3.5 CARsgen Recent Development
11.4 Nanjing Iaso Biotherapeutics
11.4.1 Nanjing Iaso Biotherapeutics Company Details
11.4.2 Nanjing Iaso Biotherapeutics Business Overview
11.4.3 Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Introduction
11.4.4 Nanjing Iaso Biotherapeutics Revenue in BCMA-targeted CAR-T Cell Therapy Business (2021–2026)
11.4.5 Nanjing Iaso Biotherapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Abecma
 Table 3. Key Players of Carvykti
 Table 4. Key Players of Others
 Table 5. Global BCMA-targeted CAR-T Cell Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global BCMA-targeted CAR-T Cell Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 7. Global BCMA-targeted CAR-T Cell Therapy Market Size by Region (US$ Million), 2021–2026
 Table 8. Global BCMA-targeted CAR-T Cell Therapy Market Share by Region (2021–2026)
 Table 9. Global BCMA-targeted CAR-T Cell Therapy Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 10. Global BCMA-targeted CAR-T Cell Therapy Market Share by Region (2027–2032)
 Table 11. BCMA-targeted CAR-T Cell Therapy Market Trends
 Table 12. BCMA-targeted CAR-T Cell Therapy Market Drivers
 Table 13. BCMA-targeted CAR-T Cell Therapy Market Challenges
 Table 14. BCMA-targeted CAR-T Cell Therapy Market Restraints
 Table 15. Global BCMA-targeted CAR-T Cell Therapy Revenue by Players (US$ Million), 2021–2026
 Table 16. Global BCMA-targeted CAR-T Cell Therapy Market Share by Players (2021–2026)
 Table 17. Global Top BCMA-targeted CAR-T Cell Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on BCMA-targeted CAR-T Cell Therapy Revenue, 2025
 Table 18. Ranking of Global Top BCMA-targeted CAR-T Cell Therapy Companies by Revenue (US$ Million) in 2025
 Table 19. Global 5 Largest Players Market Share by BCMA-targeted CAR-T Cell Therapy Revenue (CR5 and HHI), 2021–2026
 Table 20. Global Key Players of BCMA-targeted CAR-T Cell Therapy, Headquarters and Area Served
 Table 21. Global Key Players of BCMA-targeted CAR-T Cell Therapy, Products and Applications
 Table 22. Global Key Players of BCMA-targeted CAR-T Cell Therapy, Date of General Availability (GA)
 Table 23. Mergers and Acquisitions, Expansion Plans
 Table 24. Global BCMA-targeted CAR-T Cell Therapy Market Size by Type (US$ Million), 2021–2026
 Table 25. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Type (2021–2026)
 Table 26. Global BCMA-targeted CAR-T Cell Therapy Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 27. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Type (2027–2032)
 Table 28. Global BCMA-targeted CAR-T Cell Therapy Market Size by Application (US$ Million), 2021–2026
 Table 29. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021–2026)
 Table 30. Global BCMA-targeted CAR-T Cell Therapy Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 31. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Application (2027–2032)
 Table 32. North America BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 33. North America BCMA-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 34. North America BCMA-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 35. Europe BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 36. Europe BCMA-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 37. Europe BCMA-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 38. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 39. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size by Region (US$ Million), 2021–2026
 Table 40. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size by Region (US$ Million), 2027–2032
 Table 41. Latin America BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 42. Latin America BCMA-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 43. Latin America BCMA-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 44. Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 45. Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2021–2026
 Table 46. Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Size by Country (US$ Million), 2027–2032
 Table 47. Nanjing Legend Biotechnology/J&J (Carvykti) Company Details
 Table 48. Nanjing Legend Biotechnology/J&J (Carvykti) Business Overview
 Table 49. Nanjing Legend Biotechnology/J&J (Carvykti) BCMA-targeted CAR-T Cell Therapy Product
 Table 50. Nanjing Legend Biotechnology/J&J (Carvykti) Revenue in BCMA-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026
 Table 51. Nanjing Legend Biotechnology/J&J (Carvykti) Recent Development
 Table 52. Bristol-Myers Squibb (Abecma) Company Details
 Table 53. Bristol-Myers Squibb (Abecma) Business Overview
 Table 54. Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Product
 Table 55. Bristol-Myers Squibb (Abecma) Revenue in BCMA-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026
 Table 56. Bristol-Myers Squibb (Abecma) Recent Development
 Table 57. CARsgen Company Details
 Table 58. CARsgen Business Overview
 Table 59. CARsgen BCMA-targeted CAR-T Cell Therapy Product
 Table 60. CARsgen Revenue in BCMA-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026
 Table 61. CARsgen Recent Development
 Table 62. Nanjing Iaso Biotherapeutics Company Details
 Table 63. Nanjing Iaso Biotherapeutics Business Overview
 Table 64. Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Product
 Table 65. Nanjing Iaso Biotherapeutics Revenue in BCMA-targeted CAR-T Cell Therapy Business (US$ Million), 2021–2026
 Table 66. Nanjing Iaso Biotherapeutics Recent Development
 Table 67. Research Programs/Design for This Report
 Table 68. Key Data Information from Secondary Sources
 Table 69. Key Data Information from Primary Sources
 Table 70. Authors List of This Report


List of Figures
 Figure 1. BCMA-targeted CAR-T Cell Therapy Picture
 Figure 2. Global BCMA-targeted CAR-T Cell Therapy Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global BCMA-targeted CAR-T Cell Therapy Market Share by Type: 2025 vs 2032
 Figure 4. Abecma Features
 Figure 5. Carvykti Features
 Figure 6. Others Features
 Figure 7. Global BCMA-targeted CAR-T Cell Therapy Market Size by Application (US$ Million), 2021–2032
 Figure 8. Global BCMA-targeted CAR-T Cell Therapy Market Share by Application: 2025 vs 2032
 Figure 9. Hospital Case Studies
 Figure 10. Oncology Clinic Case Studies
 Figure 11. BCMA-targeted CAR-T Cell Therapy Report Years Considered
 Figure 12. Global BCMA-targeted CAR-T Cell Therapy Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 13. Global BCMA-targeted CAR-T Cell Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 14. Global BCMA-targeted CAR-T Cell Therapy Market Share by Region: 2025 vs 2032
 Figure 15. Global BCMA-targeted CAR-T Cell Therapy Market Share by Players in 2025
 Figure 16. Global BCMA-targeted CAR-T Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 17. The Top 10 and 5 Players Market Share by BCMA-targeted CAR-T Cell Therapy Revenue in 2025
 Figure 18. North America BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 19. North America BCMA-targeted CAR-T Cell Therapy Market Share by Country (2021–2032)
 Figure 20. United States BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. Canada BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Europe BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Europe BCMA-targeted CAR-T Cell Therapy Market Share by Country (2021–2032)
 Figure 24. Germany BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. France BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. U.K. BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. Italy BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Russia BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Ireland BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Asia-Pacific BCMA-targeted CAR-T Cell Therapy Market Share by Region (2021–2032)
 Figure 32. China BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Japan BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. South Korea BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. Southeast Asia BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. India BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Australia & New Zealand BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Latin America BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Latin America BCMA-targeted CAR-T Cell Therapy Market Share by Country (2021–2032)
 Figure 40. Mexico BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Brazil BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Middle East & Africa BCMA-targeted CAR-T Cell Therapy Market Share by Country (2021–2032)
 Figure 44. Israel BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Saudi Arabia BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. UAE BCMA-targeted CAR-T Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. Nanjing Legend Biotechnology/J&J (Carvykti) Revenue Growth Rate in BCMA-targeted CAR-T Cell Therapy Business (2021–2026)
 Figure 48. Bristol-Myers Squibb (Abecma) Revenue Growth Rate in BCMA-targeted CAR-T Cell Therapy Business (2021–2026)
 Figure 49. CARsgen Revenue Growth Rate in BCMA-targeted CAR-T Cell Therapy Business (2021–2026)
 Figure 50. Nanjing Iaso Biotherapeutics Revenue Growth Rate in BCMA-targeted CAR-T Cell Therapy Business (2021–2026)
 Figure 51. Bottom-up and Top-down Approaches for This Report
 Figure 52. Data Triangulation
 Figure 53. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools